HedgeChatter

  • Home /
  • Tag Archives

NVS

Novartis puts pressure on India over patent abuse

[at Financial Times] – Novartis has urged US and European governments to apply pressure on India to respect intellectual property and warned New Delhi that its stance on patents is deterring investment. Joe Jimenez, … moreView todays social media effects on NVSView the latest stocks trending across Twitter. Click to view dashboardSee who Novartis is hiring next, click here to […]

February 16, 2014 Bystocknews , Comments Off on Novartis puts pressure on India over patent abuse read more

Supreme Court denial of Glivec patent clarifies limited intellectual property protection and discourages future innovation in India »

[at noodls] – Patent denied despite global recognition of Glivec as a life-saving, breakthrough drug for certain forms of cancer, with patents granted in nearly 40 countries Novartis has never been granted an original … moreView todays social media effects on NVSView the latest stocks trending across Twitter. Click to view dashboardSee who Novartis is hiring next, click here to […]

April 1, 2013 Bystocknews , Comments Off on Supreme Court denial of Glivec patent clarifies limited intellectual property protection and discourages future innovation in India » read more

Novartis confirms growing Gilenya® clinical and real-world experience as number of patients treated increases to over 63,000 »

[at noodls] – Growing global evidence base reinforces consistent and sustained efficacy of first once-daily oral multiple sclerosis treatment Up to seven years of clinical trial experience (Phase II and III) and over … moreView todays social media effects on NVSView the latest stocks trending across Twitter. Click to view dashboardSee who Novartis is hiring next, click here to view […]

March 27, 2013 Bystocknews , Comments Off on Novartis confirms growing Gilenya® clinical and real-world experience as number of patients treated increases to over 63,000 » read more

New analysis shows Novartis drug Gilenya® significantly reduced rate of brain volume loss across three large Phase III studies »

[at noodls] – Data show reductions in rate of brain volume loss by about one-third compared to interferon beta-1a IM or placebo in studies with over 3,600 patients with relapsing MS Gilenya is the first oral disease … moreView todays social media effects on NVSView the latest stocks trending across Twitter. Click to view dashboardSee who Novartis is hiring next, […]

March 21, 2013 Bystocknews , Comments Off on New analysis shows Novartis drug Gilenya® significantly reduced rate of brain volume loss across three large Phase III studies » read more

Novartis data at AAN reinforces commitment to address high unmet medical need and to provide a treatment at every stage of multiple sclerosis »

[at noodls] – New data from three Phase III studies underlines efficacy and adds to growing global experience with Gilenya in more than 50,000 patients worldwide Data from over 500 patients treated for up to four years … moreView todays social media effects on NVSView the latest stocks trending across Twitter. Click to view dashboardSee who Novartis is hiring next, […]

March 13, 2013 Bystocknews , Comments Off on Novartis data at AAN reinforces commitment to address high unmet medical need and to provide a treatment at every stage of multiple sclerosis » read more

Novartis collaboration aims to eliminate rheumatic heart disease (RHD) in Zambia, Africa »

[at noodls] – RHD has been eliminated in most developed nations, but sub-Saharan Africa studies show at least 2-3% of school-age children suffer from this often fatal disease[1] Collaboration between Novartis physicians, … moreView todays social media effects on NVSView the latest stocks trending across Twitter. Click to view dashboardSee who Novartis is hiring next, click here to view […]

February 28, 2013 Bystocknews , Comments Off on Novartis collaboration aims to eliminate rheumatic heart disease (RHD) in Zambia, Africa » read more

Novartis reports Phase III data showing omalizumab improved itch in patients with a chronic form of hives who failed standard therapy[1] »

[at noodls] – Study published in NEJM today and presented tomorrow met primary endpoint[1] in moderate to severe refractory chronic idiopathic/spontaneous urticaria (CIU/CSU) Up to two-thirds (66%) of omalizumab patients … moreView todays social media effects on NVSView the latest stocks trending across Twitter. Click to view dashboardSee who Novartis is hiring next, click here to view […]

February 24, 2013 Bystocknews , Comments Off on Novartis reports Phase III data showing omalizumab improved itch in patients with a chronic form of hives who failed standard therapy[1] » read more

Novartis drug Zortress® is first in over a decade approved by FDA to prevent organ rejection in adult liver transplant patients »

[at noodls] – Zortress is the first mTOR inhibitor approved to prevent organ rejection in adult liver transplant patients in the US, where it is already approved for kidney transplantation Approval based on positive … moreView todays social media effects on NVSView the latest stocks trending across Twitter. Click to view dashboardSee who Novartis is hiring next, click here to […]

February 16, 2013 Bystocknews , Comments Off on Novartis drug Zortress® is first in over a decade approved by FDA to prevent organ rejection in adult liver transplant patients » read more

Novartis drug Exjade® first treatment approved by FDA for chronic iron overload in patients with non-transfusion-dependent thalassemia »

[at noodls] – Pivotal placebo-controlled study data show Exjade significantly decreases iron burden in NTDT patients versus placebo, with similar overall adverse event rate[1] Patients with NTDT accumulate excess iron … moreView todays social media effects on NVSView the latest stocks trending across Twitter. Click to view dashboardSee who Novartis is hiring next, click here to view […]

January 23, 2013 Bystocknews , Comments Off on Novartis drug Exjade® first treatment approved by FDA for chronic iron overload in patients with non-transfusion-dependent thalassemia » read more